Efzofitimod Scores FDA Fast Track Designation for SSc-ILD
The U.S. Food and Drug Administration (FDA) has granted the experimental therapy efzofitimod fast track status as a potential treatment for interstitial lung disease (ILD) associated with systemic sclerosis (SSc). The designation is given to speed up the development and review of therapies designed to treat serious health conditions.